Literature DB >> 9915506

Submental metastases from nasopharyngeal carcinoma.

A T Ahuja1, S F Leung, P Teo, M Ying, W King, C Metreweli.   

Abstract

The primary treatment for nasopharyngeal carcinoma is radiotherapy. Despite optimal treatment the incidence of recurrent persistent or recurrent regional disease is significant. It is believed that recurrent regional disease is usually associated with local disease. Recurrent nodal disease commonly involves the subdigastric and upper jugular region and submental involvement is less common. This study includes 25 patients who had palpable submental nodes 2 years or more after radiotherapy. Five of the seven patients with proven malignant submental nodal recurrence of nasopharyngeal carcinoma had no other evidence of disease. Ultrasound accurately identified enlarged nodes and correctly predicted involvement. The ultrasound appearances of these nodes and their impact on management and prognosis is discussed.

Entities:  

Mesh:

Year:  1999        PMID: 9915506     DOI: 10.1016/s0009-9260(99)91235-7

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  3 in total

1.  Is it necessary to perform radical neck dissection as a salvage procedure for persistent or recurrent neck disease after chemoradiotherapy in patients with nasopharyngeal cancer?

Authors:  Avi Khafif; Alfio Ferlito; Robert P Takes; K Thomas Robbins
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-03-30       Impact factor: 2.503

2.  Outcome of surgical management of persistent or recurrent neck mass in patients with nasopharyngeal carcinoma after radiotherapy.

Authors:  Cheng-Yu Lin; Sen-Tien Tsai; Ying-Tai Jin; Ming-Wei Yang; I-Chun Yeh; Jenn-Ren Hsiao
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-12-07       Impact factor: 2.503

3.  The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.

Authors:  Sai-Lan Liu; Xue-Song Sun; Xiao-Yun Li; Lin-Quan Tang; Qiu-Yan Chen; Huan-Xin Lin; Yu-Jing Liang; Jin-Jie Yan; Chao Lin; Shan-Shan Guo; Li-Ting Liu; Yang Li; Hao-Jun Xie; Qing-Nan Tang; Hu Liang; Ling Guo; Hai-Qiang Mai
Journal:  Cancer Commun (Lond)       Date:  2019-03-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.